April 07, 2020
Sun Pharma can't get out of Celgene's suit over a proposed generic version of the blockbuster cancer medication Revlimid, even though the patents in question aren't listed in the FDA's Orange Book, a New Jersey judge ruled Monday.
April 17, 2019
Celgene has asked a New Jersey federal court to stop Sun Pharma from moving forward with its generic version of the blockbuster cancer medication Revlimid until three patents expire.